China SXT Pharmaceuticals (SXTC) Gains from Sales and Divestitures: 2021-2025
- China SXT Pharmaceuticals' Gains from Sales and Divestitures rose 1249.18% to $22.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 million, marking a year-over-year increase of 1249.18%. This contributed to the annual value of $8.0 million for FY2024, which is 39.90% up from last year.
- According to the latest figures from Q3 2025, China SXT Pharmaceuticals' Gains from Sales and Divestitures is $22.8 million, which was up 1,249.18% from $1.7 million recorded in Q3 2024.
- China SXT Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $22.8 million during Q3 2025, with a 5-year trough of $0.30 in Q3 2023.
- Moreover, its 3-year median value for Gains from Sales and Divestitures was $5.7 million (2023), whereas its average is $7.6 million.
- Data for China SXT Pharmaceuticals' Gains from Sales and Divestitures shows a peak YoY surged of 562,754,900.00% (in 2024) over the last 5 years.
- China SXT Pharmaceuticals' Gains from Sales and Divestitures (Quarterly) stood at $2.3 million in 2021, then reached $0.30 in 2023, then spiked by 562,754,900.00% to $1.7 million in 2024, then spiked by 1,249.18% to $22.8 million in 2025.
- Its Gains from Sales and Divestitures was $22.8 million in Q3 2025, compared to $1.7 million in Q3 2024 and $8.0 million in Q1 2024.
